These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1134 related articles for article (PubMed ID: 6895729)

  • 21. Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
    Atwell GJ; Rewcastle GW; Denny WA; Cain BF; Baguley BC
    J Med Chem; 1984 Mar; 27(3):367-72. PubMed ID: 6546591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine.
    Denny WA; Atwell GJ; Baguley BC
    J Med Chem; 1984 Mar; 27(3):363-7. PubMed ID: 6546590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Frei E; Schabel FM; Goldin A
    Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
    [No Abstract]   [Full Text] [Related]  

  • 24. Antitumor action of N-(2-chloroethyl)-N-nitrosocarbamoyl derivatives of biologically active polypeptide hormone fragments.
    Jeney A; Kopper L; Nagy P; Lapis K; Süli-Vargha H; Medzihradszky K
    Cancer Chemother Pharmacol; 1986; 16(2):129-32. PubMed ID: 3948298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
    Rewcastle GW; Atwell GJ; Baguley BC; Denny WA
    J Med Chem; 1984 Aug; 27(8):1053-6. PubMed ID: 6747989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumour activity of some cyclophosphazenes.
    Labarre JF; Faucher JP; Levy G; Sournies F; Cros S; François G
    Eur J Cancer (1965); 1979 May; 15(5):637-43. PubMed ID: 510331
    [No Abstract]   [Full Text] [Related]  

  • 28. Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
    Aranha GV; Grage TB
    Minn Med; 1977 Aug; 60(8):543-8. PubMed ID: 882082
    [No Abstract]   [Full Text] [Related]  

  • 29. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
    Fujimoto S; Ogawa M
    Cancer Chemother Pharmacol; 1982; 8(2):157-62. PubMed ID: 7105379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consideration of the subcutaneously implanted B16 melanoma as a screening model for potential anticancer agents.
    Griswold DP
    Cancer Chemother Rep 2; 1972 Nov; 3(1):315-24. PubMed ID: 4660734
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of AT1727 on growth and metastasis of murine tumours.
    Li XT; Hutchinson GE; Pym BA; Finch M; Hellmann K
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):283-7. PubMed ID: 6681774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of 4'-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA, NSC 249992) on human tumors in nude mice.
    Sordillo PP; Helson L; Lesser M
    Cancer Clin Trials; 1980; 3(4):385-9. PubMed ID: 6893575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutathione metabolism as a determinant of therapeutic efficacy: a review.
    Arrick BA; Nathan CF
    Cancer Res; 1984 Oct; 44(10):4224-32. PubMed ID: 6380705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I and II study of m-AMSA in acute leukaemia.
    Slevin ML; Shannon MS; Prentice HG; Goldman AJ; Lister TA
    Cancer Chemother Pharmacol; 1981; 6(2):137-40. PubMed ID: 6946878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Some thoughts on experimental models and their clinical correlations.
    Carter SK
    Eur J Cancer (1965); 1973; 9(11-12):833-41. PubMed ID: 4804310
    [No Abstract]   [Full Text] [Related]  

  • 36. Attempted drug-tumor sensitivity matching using diffusion chamber-cultivated cells.
    Mason BH; Cain BF
    Cancer Treat Rep; 1978 Dec; 62(12):2035-43. PubMed ID: 751713
    [No Abstract]   [Full Text] [Related]  

  • 37. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
    Coates AS; Bishop J; Mann GJ; Raghavan D
    Eur J Cancer Clin Oncol; 1986 Jan; 22(1):97-100. PubMed ID: 3754214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of antitumor properties of nitracrine and amsacrine analogs.
    Mazerska Z; Chołody M; Lukowicz J; Wysocka-Skrzela B; Ledóchowski A
    Arzneimittelforschung; 1987 Nov; 37(11):1276-81. PubMed ID: 3326605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DTIC (NSC-45388) in malignant melanoma: a perspective.
    Comis RL
    Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
    [No Abstract]   [Full Text] [Related]  

  • 40. Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
    Atwell GJ; Baguley BC; Finlay GJ; Rewcastle GW; Denny WA
    J Med Chem; 1986 Sep; 29(9):1769-76. PubMed ID: 3755758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.